Handok Inc. has made a strategic partnership agreement with Lilly Korea for the domestic sales of the erectile dysfunction and benign prostatic hyperplasia treatment of ‘Cialis® tablets (key ingredient: tadalafil, hereinafter referred to as Cialis)’. Handok Inc. will now be in charge of domestic distribution, marketing and sales of ‘Cialis’.

‘Cialis’ is a treatment approved for its efficacy of treating symptoms of erectile dysfunction and benign prostatic hyperplasia, which are typical male urological conditions. Cialis was launched in Korea in 2003 and has been providing an alternative for previously limited treatment of erectile dysfunction and benign prostatic hyperplasia in order to help improve the quality of life for patients. Handok Inc. has built expertise in urology pharmaceuticals with ‘Xatral XL Tab’, a benign prostatic hyperplasia treatment, and ‘Toviaz Tab’, an overactive bladder treatment. With Cialis the company plans to provide more options for urology patients while strengthening its competitiveness and leadership in the field.